From the 1Women’s Health Research Program, Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia; 2The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia; 3CogState Ltd, Melbourne, Victoria, Australia; 4Center for Neuroscience, University of Melbourne, Parkville, Victoria, Australia; and 5Monash Biomedical Imaging, Monash University, Melbourne, Victoria, Australia.
Received November 2, 2012; revised and accepted January 10, 2013.
Australian New Zealand Clinical Trials Registration: ACTRN12608000201370.
Funding/support: This study was supported by Bayer Pharma AG (Berlin, Germany), which provided study medications and funding for the study. S.R.D. is a principal research fellow of the Australian National Health and Medical Research Council (grant 490939). No funding was provided for the analyses undertaken by the authors.
Financial disclosure/conflicts of interest: S.R.D. has served as a consultant to BioSante USA and Trimel CA and has received research funding from Bayer Pharma and BioSante USA. S.L.D. is a member of the speakers’ bureau for Jean Hailes for Women’s Health, receives paymentfor the preparation and delivery of women’s health presentations, and has received payment for the development of an educational presentation for Lawley Pharmaceuticals Pty Ltd. P.M. is a paid employee of CogState Ltd. J.L. served as research assistant at the Florey Institute during project design and data collection, for which she and the institute received payment.
The other authors declare no conflicts of interest.
Address correspondence to: Susan R. Davis, MBBS, FRACP, PhD, Women’s Health Research Program, School of Public Health and Preventive Medicine, Monash University, Level 6, The Alfred Center, 99Commercial Road, Melbourne, VIC 3004, Australia. E-mail: [email protected]
